Results 151 to 160 of about 126,219 (197)
Central Serous Chorioretinopathy in Parallel With Onset and Relapses of Minimal Change Nephrotic Syndrome: A 28-Year Case Follow-Up. [PDF]
CureusMatsuo T, Tanaka T, Wada J.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of the American Academy of Dermatology, 1986
Cyclosporin A is a new immunosuppressive agent that selectively affects T helper cells without suppressing the bone marrow. Cyclosporin A has been used primarily to prevent rejection in organ transplantation and acute graft-versus-host disease. Studies suggest that it may be of benefit in psoriasis, pemphigus vulgaris, bullous pemphigoid, Behçet's ...
E H, Page, D M, Wexler, L C, Guenther
+6 more sources
Cyclosporin A is a new immunosuppressive agent that selectively affects T helper cells without suppressing the bone marrow. Cyclosporin A has been used primarily to prevent rejection in organ transplantation and acute graft-versus-host disease. Studies suggest that it may be of benefit in psoriasis, pemphigus vulgaris, bullous pemphigoid, Behçet's ...
E H, Page, D M, Wexler, L C, Guenther
+6 more sources
Neoral: a microemulsion cyclosporine
Journal of Transplant Coordination, 1996Cyclosporine (Sandimmune), introduced in the 1980s, improved patient and graft survival rates primarily by decreasing the frequency and severity of early, acute rejection. Today, the challenge for coordinators and clinicians is to promote long-term clinical stability in transplant recipients.
openaire +2 more sources
2016
In 1976, Jean-Francois Borel et al. [1] described the possible use of cyclosporin A (CsA) for the treatment of autoimmune disease. Since then, CsA has been studied in virtually every known autoimmune disease in man, ranging from systemic lupus erythematosus (SLE), psoriasis and inflammatory bowel disease to rheumatoid arthritis and to diseases like ...
Baarsma, Goitze Seerp, Caspers, Laure
openaire +1 more source
In 1976, Jean-Francois Borel et al. [1] described the possible use of cyclosporin A (CsA) for the treatment of autoimmune disease. Since then, CsA has been studied in virtually every known autoimmune disease in man, ranging from systemic lupus erythematosus (SLE), psoriasis and inflammatory bowel disease to rheumatoid arthritis and to diseases like ...
Baarsma, Goitze Seerp, Caspers, Laure
openaire +1 more source
Annales de l'Institut Pasteur / Immunologie, 1987
Gernot Rassner, Ursula Steinert
openaire +3 more sources
Gernot Rassner, Ursula Steinert
openaire +3 more sources